Market Research Logo

Global Venous Thromboembolism Therapeutics Market 2017-2021

Global Venous Thromboembolism Therapeutics Market 2017-2021

About Venous Thromboembolism Therapeutic

The global VTE therapeutics market is expected to benefit from the growing incidence of VTE worldwide. According to the CDC, every year around 0.9 million individuals are affected by VTE in the US and 60,000 to 100,000 individuals in the US die of VTE. Further, the presence of high unmet medical needs is expected to fuel the market growth. For instance, according to the CDC approximately 50% of individuals with VTE will have long-term complications, and 33% of individuals will have a recurrence within ten years.

Technavio’s analysts forecast the global venous thromboembolism therapeutic market to grow at a CAGR of 6.40% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global venous thromboembolism therapeutic market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of VTE products in the following drug classes.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Venous Thromboembolism Therapeutic Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

key vendors
  • Bayer HealthCare
  • BMS
  • Boehringer Ingelheim
  • Daiichi Sankyo
  • Johnson & Johnson
  • Sanofi
Other prominent vendors
  • Altor Bioscience
  • Armetheon
  • Aspen Pharma
  • BioInvent International
  • eXIthera Pharmaceuticals
  • Gamma Therapeutics
  • GlycoMimetics
  • Green Cross
  • Isis Pharmaceutical
  • Leo Pharma
  • Pfizer
  • Portola Pharmaceuticals
  • ThromboGenics
Market driver
  • Increasing surgical procedures such as hip and knee replacements.
  • For a full, detailed list, view our report
Market challenge
  • Presence of alternatives such as thrombectomy and percutaneous techniques.
  • For a full, detailed list, view our report
Market trend
  • Development of drugs for new indications.
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


  • Executive summary
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
    • Highlights
  • Disease overview
    • Table Types of venous thromboembolism
    • Diagnosis of VTE
    • Treatment of VTE
  • Pipeline analysis
    • Table Pipeline analysis
    • Table Key pipeline molecules
  • Market landscape
    • Market overview
      • Table Global VTE therapeutics market snapshot
      • Table Global VTE therapeutics market 2016-2021 ($ millions)
      • Table Opportunity analysis in global venous thromboembolism market
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by drug class
    • Factor Xa inhibitors
      • Table Factor Xa inhibitors in global VTE therapeutics market 2016-2021 ($ millions)
    • Direct thrombin inhibitors
      • Table Direct thrombin inhibitors in venous thromboembolism market 2016-2021 ($ millions)
    • Heparin
      • Table Heparin in global VTE therapeutics market 2016-2021 ($ millions)
    • Vitamin K antagonists
      • Table Vitamin K antagonists in global venous thromboembolism market 2016-2021 ($ millions)
  • Geographical segmentation
    • Table Segmentation of global VTE therapeutics market based on geography 2016 and 2021
    • Table VTE therapeutics market revenue by geography 2016-2021 (%)
    • VTE therapeutics market in Americas
      • Table Market scenario in Americas
      • Table VTE therapeutics market in Americas 2016-2021 ($ millions)
    • VTE therapeutics market in EMEA
      • Table Market scenario in EMEA
      • Table VTE therapeutics market in EMEA ($ millions)
    • VTE therapeutics market in APAC
      • Table Market scenario in APAC
      • Table Venous thromboembolism therapeutics market in APAC ($ millions)
  • Market drivers
    • Increasing adoption of NOACs
    • Increasing surgical procedures such as hip and knee replacements
    • Large patient pool coupled with growing awareness campaigns
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Presence of alternatives such as thrombectomy and percutaneous techniques
    • Unmet needs for anticoagulant reversal agents
    • Extensive use of generic products
      • Table Forcefield analysis of drivers and challenges
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Development of drugs for new indications
    • Growing focus on emerging economies
    • Patient assistance programs
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure analysis of global VTE therapeutics market 2015
      • Table Competitive analysis of global VTE therapeutics market 2016
      • Table Market share analysis 2015
      • Table Market penetration of various VTE manufacturers worldwide 2016
      • Table Strategic success factors of companies in global VTE therapeutics market
  • Key vendor analysis
    • Bayer HealthCare
      • Table Bayer HealthCare: Key highlights
      • Table Bayer HealthCare: Strength assessment
      • Table Bayer HealthCare: Strategy assessment
      • Table Bayer HealthCare: Opportunity assessment
      • Table Bayer HealthCare: YoY revenue and growth rate of Xarelto 2013-2015 ($ billions)
    • BMS
      • Table BMS: Key highlights
      • Table BMS: Strength assessment
      • Table BMS: Strategy assessment
      • Table BMS: Opportunity assessment
      • Table BMS: YoY revenue and growth rate of Eliquis (outside the US) 2013-2015 ($ millions)
      • Table Geographic segmentation of Eliquis 2015
    • Boehringer Ingelheim
      • Table Boehringer Ingelheim: Key highlights
      • Table Boehringer Ingelheim: Strength assessment
      • Table Boehringer Ingelheim: Strategy assessment
      • Table Boehringer Ingelheim: Opportunity assessment
      • Table Boehringer Ingelheim: YoY revenue and growth rate of Pradaxa (Global) 2013-2015 ($ billions)
    • Daiichi Sankyo
      • Table Daiichi Sankyo: Key highlights
      • Table Daiichi Sankyo: Strength assessment
      • Table Daiichi Sankyo: Strategy assessment
      • Table Daiichi Sankyo: Opportunity assessment
    • Johnson & Johnson
      • Table Johnson & Johnson: Key highlights
      • Table Johnson & Johnson: Strength assessment
      • Table Johnson & Johnson: Strategy assessment
      • Table Johnson & Johnson: Opportunity assessment
      • Table Johnson & Johnson: YoY revenue and growth rate of Xarelto 2013-2015 ($ millions)
    • Sanofi
      • Table Sanofi: Key highlights
      • Table Sanofi: Strength assessment
      • Table Sanofi: Strategy assessment
      • Table Sanofi: Opportunity assessment
      • Table Sanofi: YoY revenue and growth rate of Lovenox 2013-2015 ($ billions)
      • Table Geographical segmentation of Lovenox 2015
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report